BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Agni RM. Diagnostic histopathology of hepatocellular carcinoma: A case-based review. Semin Diagn Pathol. 2017;34:126-137. [PMID: 28143798 DOI: 10.1053/j.semdp.2016.12.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Bello HR, Mahdi ZK, Lui SK, Nandwana SB, Harri PA, Davarpanah AH. Hepatocellular Carcinoma With Atypical Imaging Features: Review of the Morphologic Hepatocellular Carcinoma Subtypes With Radiology-Pathology Correlation. J Magn Reson Imaging 2021. [PMID: 33682266 DOI: 10.1002/jmri.27553] [Reference Citation Analysis]
2 Rastogi A. Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma. World J Gastroenterol 2018; 24(35): 4000-4013 [PMID: 30254404 DOI: 10.3748/wjg.v24.i35.4000] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
3 Karadag Soylu N. Update on Hepatocellular Carcinoma: a Brief Review from Pathologist Standpoint. J Gastrointest Cancer 2020;51:1176-86. [PMID: 32844348 DOI: 10.1007/s12029-020-00499-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
4 Renzulli M, Brandi N, Argalia G, Brocchi S, Farolfi A, Fanti S, Golfieri R. Morphological, dynamic and functional characteristics of liver pseudolesions and benign lesions. Radiol Med 2022. [PMID: 35028886 DOI: 10.1007/s11547-022-01449-w] [Reference Citation Analysis]
5 Bösmüller H, Pfefferle V, Bittar Z, Scheble V, Horger M, Sipos B, Fend F. Microvessel density and angiogenesis in primary hepatic malignancies: Differential expression of CD31 and VEGFR-2 in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Pathol Res Pract 2018;214:1136-41. [PMID: 29935812 DOI: 10.1016/j.prp.2018.06.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
6 Low HM, Choi JY, Tan CH. Pathological variants of hepatocellular carcinoma on MRI: emphasis on histopathologic correlation. Abdom Radiol (NY) 2019;44:493-508. [PMID: 30145629 DOI: 10.1007/s00261-018-1749-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
7 Ye L, Zhu L, Wang J, Li F. Inhibition of vitamin D analog eldecalcitol on hepatoma in vitro and in vivo. Open Med (Wars) 2020;15:663-71. [PMID: 33336024 DOI: 10.1515/med-2020-0137] [Reference Citation Analysis]
8 Bakheet AMH, Zhao C, Chen JN, Zhang JY, Huang JT, Du Y, Gong LP, Bi YH, Shao CK. Improving pathological early diagnosis and differential biomarker value for hepatocellular carcinoma via RNAscope technology. Hepatol Int 2020;14:96-104. [PMID: 31832976 DOI: 10.1007/s12072-019-10006-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
9 Samdanci ET, Akatli AN, Soylu NK. Clinicopathological Features of Two Extremely Rare Hepatocellular Carcinoma Variants: a Brief Review of Fibrolamellar and Scirrhous Hepatocellular Carcinoma. J Gastrointest Cancer 2020;51:1187-92. [PMID: 32860202 DOI: 10.1007/s12029-020-00500-1] [Reference Citation Analysis]
10 Sempoux C, Balabaud C, Paradis V, Bioulac-Sage P. Hepatocellular nodules in vascular liver diseases. Virchows Arch 2018;473:33-44. [PMID: 29804132 DOI: 10.1007/s00428-018-2373-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
11 Xiong MJ, Patel CR, Manne U, Al Diffalha S. Cirrhotomimetic hepatocellular carcinoma: experience of a single institution and review of the literature. Hepat Oncol 2020;8:HEP28. [PMID: 33680429 DOI: 10.2217/hep-2020-0015] [Reference Citation Analysis]
12 Vij M, Calderaro J. Pathologic and molecular features of hepatocellular carcinoma: An update. World J Hepatol 2021; 13(4): 393-410 [PMID: 33959223 DOI: 10.4254/wjh.v13.i4.393] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Yang G, Xu Q, Wan Y, Zhang L, Wang L, Meng F. Circ-CSPP1 knockdown suppresses hepatocellular carcinoma progression through miR-493-5p releasing-mediated HMGB1 downregulation. Cell Signal 2021;86:110065. [PMID: 34182091 DOI: 10.1016/j.cellsig.2021.110065] [Reference Citation Analysis]
14 Ma W, Shen H, Li Q, Song H, Guo Y, Li F, Zhou X, Guo X, Shi J, Cui Q, Xing J, Deng J, Yu Y, Liu W, Zhao H. MARVELD1 attenuates arsenic trioxide-induced apoptosis in liver cancer cells by inhibiting reactive oxygen species production. Ann Transl Med 2019;7:200. [PMID: 31205918 DOI: 10.21037/atm.2019.04.38] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Dos Santos ML, França A, Lima Filho ACM, Florentino RM, Diniz PH, Oliveira Lemos F, Gonçalves CAX, Coelho VL, Lima CX, Foureaux G, Nathanson MH, Vidigal PVT, Leite MF. Inositol 1,4,5-trisphosphate receptor type 3 is involved in resistance to apoptosis and maintenance of human hepatocellular carcinoma. Oncol Lett 2022;23:32. [PMID: 34966448 DOI: 10.3892/ol.2021.13150] [Reference Citation Analysis]